Maternal Respiratory Syncytial Virus Vaccine Preparedness Quality and Innovation Collective
Maternal Respiratory Syncytial Virus (RSV) Vaccine Preparedness Quality and Innovation Collective (QuIC) AMGA’s new Quality and Innovation Collective (QuIC) on Maternal Respiratory Syncytial Virus (RSV) Vaccine Preparedness aims to improve care of infants at risk for RSV by maternal RSV vaccination and to raise awareness of the burden of RSV disease.
-
According to the Centers for Disease Control and Prevention (CDC), each year in the United States, RSV leads to approximately 58,000-80,000 hospitalizations among children younger than 5 years old.
-
On August 21, 2023, the Food and Drug Administration approved the first vaccine for use against RSV during the 32 to 36 weeks of pregnancy to protect infants from birth through 6 months of age. On September 22, 2023, CDC's Advisory Committee on Immunization Practices (ACIP) issued routine recommendations for its use, and these recommendations have been published in the Morbidity and Mortality Weekly Report (MMWR) following signoff by the CDC director.
AMGA’s Maternal RSV QuIC is a three-phase initiative, combining an educational webinar and virtual discussion forum, a one-day virtual meeting, and a two-day in-person meeting. This QuIC utilizes interactive workshops with quality improvement tools and qualitative methodology to engage AMGA member organizations in thoughtful discussions to collect insights and share best practices on creating and implementing successful immunization rollout strategies at their organizations.
10 healthcare organizations were selected to participate in the QuIC:
Advocate Aurora Medical Group
The Everett Clinic, Part of Optum
Inova
Lehigh Valley Physician Group
Northwell Health
Olmstead Medical Center
Oregon Health & Science University, School of Medicine
Shannon Health System
Valley Health System
Vanderbilt University Medical Center
RSV Maternal Vaccine Preparedness QuIC - Interim Report and Lessons Learned
Best Practice Guide for Implementing an RSV Maternal Immunization Program
Participating health systems identified 5 areas of focus that are critical for successful implementation of an RSV maternal program and shared their experience and insights from Season 1—the first RSV season after the CDC’s Advisory Committee on Immunization Practices issued its recommendation for the vaccine on September 22, 2023— within their respective organizations. Click here to download the interim report and lessons learned document.
Maternal RSV QuIC Advisory Committee
-
Elisabeth M. Stambaugh, MD, MMM, Chief Medical Officer, Wake Forest Health Network
-
Raminder Khangura, MD, Maternal Fetal Medicine, Women's Health Services, Henry Ford Health
-
Christopher J. Russo MD MBA FAAP, Director of Pediatrics, Women and Children Services, Medical Director for Quality and Innovation, WellSpan Health
-
Sarah Pugh, PhD, Senior Director, US Medical Affairs, Vaccines, Pfizer
November & December 2023
LISTEN: Virtual Discussion Forum
Listen and engage in:
-
A live 1-hour educational webinar on maternal RSV vaccine
-
Vaccine program within your organizations
-
Click here to download the QuIC Phase 1 Meeting Summary
May 2024
SHARE: Two-Day Virtual Meeting
Share in educational sessions and interactive activities current practices of bringing a new vaccine into the organization's workflow, barriers, and plans for implementation of tailored interventions
October 2024
CREATE: Two-day In-Person Meeting, Baltimore, MD
Create and engage in:
-
A meeting on your organization's next steps for a newly approved vaccine
-
Hands-on and interactive learning with direct goals and objectives
-
A meeting that will incorporate group work, roundtables, panels, and lecture presentations, and offers participants opportunities to collaborate with one another in a structured learning environment
If your organization is interested in learning more, please contact Senait Temesgen
The Maternal RSV QuIC is sponsored by
